On July 12, 2012, Geron Corporation ("Geron") entered into the second amendment
(the "Second Amendment") to the Exclusive License Agreement (the "License")
between Geron and Angiochem, Inc. ("Angiochem") effective as of July 9, 2012. The License, dated December 6, 2010, as amended, provides Geron with a worldwide exclusive license to Angiochem's proprietary peptide technology that facilitates the transfer of anti-cancer compounds across the blood-brain barrier to be used with tubulin disassembly inhibitors to enable the treatment of primary brain cancers and cancers that have metastasized to the brain. Pursuant to the Second Amendment, the parties modified the events (and the timing thereof) that trigger certain of Geron's milestone payment obligations under the License; however, the aggregate amount of the milestones payable by Geron under the License remains unchanged.

The foregoing description of the Second Amendment is not complete and is qualified in its entirety by reference to the full text of such amendment, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

(d) Exhibits.

Exhibit Number                               Description

    10.1 †       Second Amendment to Exclusive License Agreement by and between Geron
                 Corporation and Angiochem, Inc., made effective as of July 9, 2012

† Confidential treatment has been requested for certain portions of this exhibit. Omitted information has been filed separately with the Securities and Exchange Commission.